p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.

Abstract:

:The p210 bcr-abl fusion protein tyrosine kinase oncogene has been implicated in the pathogenesis of chronic granulocytic leukemia (CGL). Specific intracellular functions performed by p210 bcr-abl have recently been delineated. We considered the possibility that p210 bcr-abl may also regulate the abundance of inosine 5'-monophosphate dehydrogenase (IMPDH) which is a rate-limiting enzyme for de novo guanylate synthesis. We performed studies of the inhibition of IMPDH by tiazofurin, which acts as a competitive inhibitor through its active species that mimics nicotinamide adenine dinucleotide (NAD), i.e. thiazole-4-carboxamide adenine dinucleotide (TAD). The mean inhibitory concentration (IC50) of tiazofurin for cellular proliferation inhibition was 2.3-2.8-fold greater in cells expressing p210 bcr-abl than in their corresponding parent cells proliferating under the influence of growth factors or in growth factor-independent derivative cells not expressing detectable p210 bcr-abl. IMPDH activity was 1.5-2.3-fold greater within cells expressing p210 bcr-abl than in their parent cells. This increase in enzyme activity was a result of 2-fold increased IMPDH protein as determined by immunoblotting. In addition, an increase in the Km value for NAD utilization by IMPDH was observed in p210 bcr-abl transformed cells, but this increase was within the range of resident NAD concentrations observed in the cells. Increased IMPDH protein in p210 bcr-abl transformed cells was traced to an increased level of IMP dehydrogenase II messenger RNA. Thus, regulation of IMPDH gene expression is mediated at least in part by the bcr-abl gene product and may therefore be indicative of a specific mechanism of intrinsic resistance to tiazofurin.

journal_name

Leukemia

journal_title

Leukemia

authors

Gharehbaghi K,Burgess GS,Collart FR,Litz-Jackson S,Huberman E,Jayaram HN,Boswell HS

subject

Has Abstract

pub_date

1994-08-01 00:00:00

pages

1257-63

issue

8

eissn

0887-6924

issn

1476-5551

journal_volume

8

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Pathogenesis and prevention of HTLV-1-associated diseases.

    abstract::HTLV-1 is an important factor involved in various diseases including adult T-cell leukemia/lymphoma and HTLV-1 associated myelopathy/tropical spastic paraparesis. Amount of HTLV-1 provirus integrated in human peripheral blood mononuclear cells might be a candidate for a risk factor in the manifestation of HTLV-1 assoc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Miwa M,Kushida S,Maeda N,Fang J,Kawamura T,Kameyama T,Uchida K

    更新日期:1997-04-01 00:00:00

  • Localization of the chromosome 15 breakpoints and expression of multiple PML-RAR alpha transcripts in acute promyelocytic leukemia: a study of 28 Chinese patients.

    abstract::Translocation (15;17)(q22;q12-q21) is a chromosome aberration specifically found in acute promyelocytic leukemia (APL), that generates a chimeric gene between the promyelocytic leukemia (PML) gene on chromosome 15 and the retinoic acid receptor alpha (RARA) gene, on chromosome 17. In the course of molecular investigat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Geng JP,Tong JH,Dong S,Wang ZY,Chen SJ,Chen Z,Zelent A,Berger R,Larsen CJ

    更新日期:1993-01-01 00:00:00

  • Leukemogenesis by the chromosomal translocations.

    abstract::The AML1 is the most commonly involved transcription factor gene in human leukemias and forms chimeric transcription factor genes, namely, AML1/MTG8 by the t(8;21), AML1/EVI-1 by the t(3;21), and TEL/AML1 by the t(12;21). The AML1a and AML1b, two isoforms of the AML1 protein, are translated from the AML1 gene by the a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Mitani K

    更新日期:1997-04-01 00:00:00

  • Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: cytogenetic and FISH evidence for a late event.

    abstract::A patient with the M2 subtype of AML who had a 45,X,-X,t(8;21) karyotype at diagnosis was found to have the Ph chromosome in one out of 37 evaluated cells 18 months after the initial diagnosis. Interphase FISH studies utilizing a BCR-ABL dual-color probe did not detect a fusion product 4 months prior to the appearance...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2400974

    authors: Najfeld V,Geller M,Troy K,Scalise A

    更新日期:1998-04-01 00:00:00

  • Myeloid to lymphoid clonal succession following autologous transplantation in second chronic phase of chronic myeloid leukaemia.

    abstract::A 23-year-old male found to have Philadelphia chromosome-positive chronic myeloid leukemia (CML) in May 1987 suffered a myeloid blastic transformation in April 1993. A second chronic phase was achieved after treatment with daunorubicin and cytosine arabinoside and the patient then underwent autologous bone marrow tran...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Spencer A,Vulliamy T,Chase A,Goldman JM

    更新日期:1995-12-01 00:00:00

  • Clinical relevance of minimal residual disease monitoring in non-Hodgkin's lymphomas: a critical reappraisal of molecular strategies.

    abstract::Although current treatments can induce clinical complete remissions in the vast majority of patients with indolent lymphoma, most of them actually relapse, because of the persistence of residual tumor cells which are undetectable using conventional diagnostic procedures. Polymerase chain reaction (PCR)-based methods a...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401559

    authors: Corradini P,Ladetto M,Pileri A,Tarella C

    更新日期:1999-11-01 00:00:00

  • Development of CAR-T cell therapies for multiple myeloma.

    abstract::Currently available data on chimeric antigen receptor (CAR)-T cell therapy has demonstrated efficacy and manageable toxicity in heavily pretreated multiple myeloma (MM) patients. The CAR-T field in MM is rapidly evolving with >50 currently ongoing clinical trials across all phases, different CAR-T design, or targets. ...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/s41375-020-0930-x

    authors: Gagelmann N,Riecken K,Wolschke C,Berger C,Ayuk FA,Fehse B,Kröger N

    更新日期:2020-09-01 00:00:00

  • Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas.

    abstract::Mantle cell lymphoma represent a clinicopathologically distinct entity of malignant non-Hodgkin's lymphoma (NHL) and are characterized by a specific chromosomal translocation t(11;14)(q13;q32) involving the cyclin D1 gene also designated as bcl-1/PRAD1 gene on chromosome 11 and the heavy chain immunoglobulin joining r...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401172

    authors: Pott C,Tiemann M,Linke B,Ott MM,von Hofen M,Bolz I,Hiddemann W,Parwaresch R,Kneba M

    更新日期:1998-10-01 00:00:00

  • Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines.

    abstract::Previous studies demonstrated that triazene compounds (TZC) possess antitumor, antimetastatic and immunosuppressive activity, and induce novel antigenic properties in neoplastic cells. Moreover, TZC showed marked antitumor activity in patients with acute myelogenous leukemias (AML). In most cases leukemic blasts with ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Tentori L,Graziani G,Gilberti S,Lacal PM,Bonmassar E,D'Atri S

    更新日期:1995-11-01 00:00:00

  • HTLV-1-like particles and HTLV-1-related DNA sequences in an unambiguous case of Sèzary syndrome.

    abstract::An unambiguous case of Sèzary syndrome associated with the presence of unusual retroviral infection markers is described. The blood smear showed 15% typical Sèzary cells but also rare atypical lymphocytes with convoluted nuclei, evocative of characteristic adult T-cell leukemia (ATL) flower cells. However, the patient...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bazarbachi A,Saal F,Laroche L,Lasneret J,Gessain A,Daniel MT,Périès J

    更新日期:1994-01-01 00:00:00

  • Dissecting the pathways to death.

    abstract::This report summarizes recent findings in the field of basic and translational apoptosis research which were presented at the 1st Conference on 'Mechanisms of Cell Death and Disease: Advances in Therapeutic Intervention' organized by the European School of Hematology and the University of Texas MD Anderson Cancer Cent...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2401940

    authors: Daniel PT

    更新日期:2000-12-01 00:00:00

  • Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.

    abstract::In this study, we compared immunoglobulin heavy-chain-gene-based minimal residual disease (MRD) detection by real-time quantitative PCR (RQ-PCR) and next-generation sequencing (NGS) to assess whether NGS could overcome some limitations of RQ-PCR and further increase sensitivity, specificity, accuracy and reproducibili...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.375

    authors: Ladetto M,Brüggemann M,Monitillo L,Ferrero S,Pepin F,Drandi D,Barbero D,Palumbo A,Passera R,Boccadoro M,Ritgen M,Gökbuget N,Zheng J,Carlton V,Trautmann H,Faham M,Pott C

    更新日期:2014-06-01 00:00:00

  • Examination of a role for idiotypy in the disease remission of a long-term survivor of adult T cell leukemia treated with anti-Tac antibody.

    abstract::The alpha chain of the interleukin 2 receptor (IL2R alpha; Tac) was targeted in clinical trials with adult T cell leukemia using murine anti-Tac antibody. Of 19 patients, a single individual achieved a durable complete remission. The mechanism of this action by murine anti-Tac has not been defined. We examined the hyp...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401048

    authors: Kingsbury GA,Waldmann TA,Junghans RP

    更新日期:1998-06-01 00:00:00

  • Large deletions 5' to the ETO breakpoint are recurrent events in patients with t(8;21) acute myeloid leukemia.

    abstract::Recurrent chromosomal rearrangements are observed in many leukemia subtypes. Recently, it has been shown that several of these translocations/inversions were associated with the loss of sequences located in the vicinity of the chromosomal breakpoints. So far, such deletions have not been described for the t(8;21) tran...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402585

    authors: Godon C,Proffitt J,Dastugue N,Lafage-Pochitaloff M,Mozziconacci MJ,Talmant P,Hackbarth M,Bataille R,Avet-Loiseau H

    更新日期:2002-09-01 00:00:00

  • Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group.

    abstract::A prospective multicenter study was performed to investigate the clinical and molecular results of intensified double induction therapy including high-dose cytarabine (ara-C) in combination with ATRA in newly diagnosed acute promyelocytic leukemia (APL), followed by consolidation and 3 years maintenance therapy. Fifty...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/sj.leu.2401843

    authors: Lengfelder E,Reichert A,Schoch C,Haase D,Haferlach T,Löffler H,Staib P,Heyll A,Seifarth W,Saussele S,Fonatsch C,Gassmann W,Ludwig WD,Hochhaus A,Beelen D,Aul C,Sauerland MC,Heinecke A,Hehlmann R,Wörmann B,Hiddemann

    更新日期:2000-08-01 00:00:00

  • Homoharringtonine in combination with cytarabine and aclarubicin resulted in high complete remission rate after the first induction therapy in patients with de novo acute myeloid leukemia.

    abstract::To assess the efficacy and toxicity of HAA regimen (homoharritonine 4 mg/m2/day, days 1-3; cytarabine 150 mg/m2/day, days 1-7; aclarubicin 12 mg/m2/day, days 1-7) as an induction therapy in the treatment of de novo acute myeloid leukemia (AML), 48 patients with newly diagnosed AML, aged 35 (14-57) years, were entered ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404287

    authors: Jin J,Jiang DZ,Mai WY,Meng HT,Qian WB,Tong HY,Huang J,Mao LP,Tong Y,Wang L,Chen ZM,Xu WL

    更新日期:2006-08-01 00:00:00

  • Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network.

    abstract::Vaccination is one of the most successful medical interventions that has saved the life of millions of people. Vaccination is particularly important in patients with multiple myeloma, who have an increased risk of infections due to the disease-inherent immune suppression, and because of the immune suppressive effects ...

    journal_title:Leukemia

    pub_type: 杂志文章,meta分析,评审

    doi:10.1038/s41375-020-01016-0

    authors: Ludwig H,Boccadoro M,Moreau P,San-Miguel J,Cavo M,Pawlyn C,Zweegman S,Facon T,Driessen C,Hajek R,Dimopoulos MA,Gay F,Avet-Loiseau H,Terpos E,Zojer N,Mohty M,Mateos MV,Einsele H,Delforge M,Caers J,Weisel K,Jackso

    更新日期:2021-01-01 00:00:00

  • Expression of the CEA gene family members NCA-50/90 and NCA-160 (CD66) in childhood acute lymphoblastic leukemias (ALLs) and in cell lines of B-cell origin.

    abstract::The carcinoembryonic antigen (CEA) and the classical non-specific cross-reacting antigens (NCAs) belong to the CEA gene family which is part of the immunoglobulin superfamily. In normal hematopoiesis, CEA gene family members (CGMs) have only been reported on cells of myeloid and monocytic origin. In the present study,...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Hanenberg H,Baumann M,Quentin I,Nagel G,Grosse-Wilde H,von Kleist S,Göbel U,Burdach S,Grunert F

    更新日期:1994-12-01 00:00:00

  • KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.

    abstract::Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity can lead to human diseases including developmental disorders and cancer. Through...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-1001-z

    authors: Au YZ,Gu M,De Braekeleer E,Gozdecka M,Aspris D,Tarumoto Y,Cooper J,Yu J,Ong SH,Chen X,Tzelepis K,Huntly BJP,Vassiliou G,Yusa K

    更新日期:2020-08-06 00:00:00

  • Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015.

    abstract::We assessed the epidemiologic progress against childhood and adolescent acute lymphoblastic leukaemia (ALL) in the Netherlands over a 26 year period. ALL patients <18 years were selected from the Netherlands Cancer Registry and the Dutch Childhood Oncology Group. Trend analyses were performed over time and by age grou...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01024-0

    authors: Reedijk AMJ,Coebergh JWW,de Groot-Kruseman HA,van der Sluis IM,Kremer LC,Karim-Kos HE,Pieters R

    更新日期:2020-08-21 00:00:00

  • C3b receptors mediate the growth factor-induced proliferation of malignant B-chronic lymphocytic leukemia lymphocytes.

    abstract::We have investigated the function of C3b receptor (CR1) in the malignant lymphocytes of B-chronic lymphocytic leukemia (B-CLL) mimicking the physiological ligand C3b with the anti-CR1 monoclonal antibody CB04 covalently linked to Sepharose CL-4B (CB04-S). The binding of insolubilized CB04-S to CR1 gave a progression s...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Caligaris-Cappio F,Schena M,Bergui L,Tesio L,Riva M,Rege-Cambrin G,Funaro A,Malavasi F

    更新日期:1987-11-01 00:00:00

  • Deletion analysis of chromosome 13q14.3 and characterisation of an alternative splice form of LEU1 in B cell chronic lymphocytic leukemia.

    abstract::Heterozygous and homozygous deletions of chromosome 13q14.3 are found in 50% of patients with B cell CLL, suggesting the presence of one or more tumour suppressor genes within the deleted region. To identify candidate genes from the region, we constructed a map of 13q14.3 using a combination of genomic and cDNA librar...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402551

    authors: Rowntree C,Duke V,Panayiotidis P,Kotsi P,Palmisano GL,Hoffbrand AV,Foroni L

    更新日期:2002-07-01 00:00:00

  • Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha.

    abstract::Signal transducer and activator of transcription (Stat)3 is constitutively activated in cutaneous T-cell lymphoma (CTCL), where it protects tumour cells against apoptosis. The constitutive activation of Stat3 leads to a constitutive expression of suppressor of cytokine signalling (SOCS)-3. In healthy cells, SOCS-3 is ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403610

    authors: Brender C,Lovato P,Sommer VH,Woetmann A,Mathiesen AM,Geisler C,Wasik M,Ødum N

    更新日期:2005-02-01 00:00:00

  • Induction treatment of acute promyelocytic leukemia using all-trans retinoic acid. Controversies about dosage, advantages and side-effect management.

    abstract::All-trans retinoic acid (ATRA) in acute promyelocytic leukemia (APL) represents the leading example of targetted drugs for inducing an in vivo differentiation of malignancy (1,2). A fixed dose of 45 mg/m2/day was proposed for the treatment of patients (3), according to the results obtained by retinoic acid derivatives...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Dombret H,Castaigne S,Fenaux P,Chomienne C,Degos L

    更新日期:1994-01-01 00:00:00

  • Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo.

    abstract::P38α/β has been described as a tumor-suppressor controlling cell cycle checkpoints and senescence in epithelial malignancies. However, p38α/β also regulates other cellular processes. Here, we describe a role of p38α/β as a regulator of acute lymphoblastic leukemia (ALL) proliferation and survival in experimental ALL m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2015.153

    authors: Alsadeq A,Strube S,Krause S,Carlet M,Jeremias I,Vokuhl C,Loges S,Aguirre-Ghiso JA,Trauzold A,Cario G,Stanulla M,Schrappe M,Schewe DM

    更新日期:2015-12-01 00:00:00

  • Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.

    abstract::The inv(16)(p13q22) chromosomal rearrangement associated with FAB M4Eo acute myeloid leukemia (AML) subtype is characterized by the presence of the CBFbeta/MYH11 fusion transcript that can be used to detect minimal residual disease (MRD). However, qualitative RT-PCR studies of MRD have so far produced conflicting resu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402478

    authors: Guerrasio A,Pilatrino C,De Micheli D,Cilloni D,Serra A,Gottardi E,Parziale A,Marmont F,Diverio D,Divona M,Lo Coco F,Saglio G

    更新日期:2002-06-01 00:00:00

  • Detection of illegitimate rearrangements within the immunoglobulin light chain loci in B cell malignancies using end sequenced probes.

    abstract::Translocations involving the immunoglobulin loci are recurring events of B cell oncogenesis. The majority of translocations involve the immunoglobulin heavy chain (IGH) locus, while a minor part involves the immunoglobulin light chain loci consisting of the kappa light chain (IGK) located at 2p11.2 and the lambda ligh...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402648

    authors: Poulsen TS,Silahtaroglu AN,Gisselø CG,Tommerup N,Johnsen HE

    更新日期:2002-10-01 00:00:00

  • Complex landscape of alternative splicing in myeloid neoplasms.

    abstract::Myeloid neoplasms are characterized by frequent mutations in at least seven components of the spliceosome that have distinct roles in the process of pre-mRNA splicing. Hotspot mutations in SF3B1, SRSF2, U2AF1 and loss of function mutations in ZRSR2 have revealed widely different aberrant splicing signatures with littl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-1002-y

    authors: Hershberger CE,Moyer DC,Adema V,Kerr CM,Walter W,Hutter S,Meggendorfer M,Baer C,Kern W,Nadarajah N,Twardziok S,Sekeres MA,Haferlach C,Haferlach T,Maciejewski JP,Padgett RA

    更新日期:2020-08-04 00:00:00

  • Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

    abstract::The fms-related tyrosine kinase 3 (FLT3) receptor has been extensively studied over the past two decades with regard to oncogenic alterations that do not only serve as prognostic markers but also as therapeutic targets in acute myeloid leukemia (AML). Internal tandem duplications (ITDs) became of special interest in t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.257

    authors: Reiter K,Polzer H,Krupka C,Maiser A,Vick B,Rothenberg-Thurley M,Metzeler KH,Dörfel D,Salih HR,Jung G,Nößner E,Jeremias I,Hiddemann W,Leonhardt H,Spiekermann K,Subklewe M,Greif PA

    更新日期:2018-02-01 00:00:00

  • Haplotype study of microsatellites flanking the t(15;17) breakpoint in acute promyelocytic leukemia patients from North Portugal.

    abstract::A higher frequency of acute promyelocytic leukemia (APL) has been noted in countries of Southern Europe and among 'Latino' patients of the United States with acute myeloid leukemia (AML). In order to discover whether there is any genetic predisposition to the disease, we analyzed microsatellites flanking PML and RARal...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402525

    authors: Martins S,Trigo F,Azevedo L,Silva MJ,Guimaraes JE,Amorim A

    更新日期:2002-07-01 00:00:00